Literature DB >> 29073727

Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx.

Zhongming Lu1,2, Erich M Sturgis2,3, Lijun Zhu2,4, Hua Zhang2,5, Ye Tao2,6, Peng Wei7, Qingyi Wei8, Guojun Li2,3.   

Abstract

Given the crucial role of Mouse double minute 4 (MDM4) oncoprotein in p53 pathway, single nucleotide polymorphisms (SNPs) could serve as such biomarkers for prediction of SCCOP recurrence. Thus, we investigated associations between three tagging putatively functional variants of MDM4, two in the 3' untranslated region of 3' UTR [rs11801299 (NC_000001.10:g.204529084G>A) and rs10900598(NC_000001.10:g.204525568G>T)] and one in intron 1 [rs1380576(NC_000001.10:g.204488278G>C)], and recurrence risk of SCCOP in 1,008 incident patients. A log-rank test and multivariable Cox models were used to assess associations. Patients with MDM4-rs10900598 GT/TT had a worse disease-free survival (DFS) compared with corresponding GG genotype, while those with rs11801299 AG/AA genotypes had a lower recurrence risk than the cases with rs11801299 GG genotype (both log-rank, P < 0.001). Multivariable analysis showed that significantly different recurrence risk were found among patients with MDM4-rs10900598 GT/TT and rs11801299 AG/AA variant genotypes (HR, 2.0, 95% CI, 1.4-2.9 and HR, 0.4, 95% CI, 0.3-0.6, respectively) compared with their corresponding common homozygous genotypes. Furthermore, after combining the risk genotypes of the three SNPs, patients among low-risk group had a significantly lower risk of SCCOP recurrence than those in high-risk group (HR, 0.2, 95% CI, 0.1-0.3). The risk for both individual SNPs or combined risk genotypes was restricted to HPV-positive SCCOP patients. Our findings suggest that the MDM4 polymorphisms may, individually or in combination, confer an independent risk of SCCOP recurrence, particularly in HPV-positive SCCOP patients. However, larger studies are needed to validate our findings.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  MDM4 polymorphism; biomarkers; human papillomavirus; oropharyngeal neoplasm; recurrence

Mesh:

Substances:

Year:  2017        PMID: 29073727      PMCID: PMC5796850          DOI: 10.1002/mc.22760

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  36 in total

1.  Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.

Authors:  D A Sharp; S A Kratowicz; M J Sank; D L George
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

Review 2.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

Review 3.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.

Authors:  J-C Marine; S Francoz; M Maetens; G Wahl; F Toledo; G Lozano
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

4.  Promoter and 3'-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the rotterdam study.

Authors:  Yue Fang; Joyce B J van Meurs; Arnold d'Alesio; Mila Jhamai; Hongyan Zhao; Fernando Rivadeneira; Albert Hofman; Johannes P T van Leeuwen; Frédéric Jehan; Huibert A P Pols; André G Uitterlinden
Journal:  Am J Hum Genet       Date:  2005-09-26       Impact factor: 11.025

Review 5.  Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

6.  Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.

Authors:  Tong Sun; Gwo-Shu Mary Lee; William K Oh; Mark Pomerantz; Ming Yang; Wanling Xie; Matthew L Freedman; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2010-09-20       Impact factor: 12.531

7.  Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Li-E Wang; Zhensheng Liu; Sheng Wei; Guojun Li; Erich M Sturgis; Qingyi Wei
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

8.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

9.  Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Authors:  Samanta Salvi; Daniele Calistri; Giorgia Gurioli; Elisa Carretta; Luigi Serra; Roberta Gunelli; Wainer Zoli; Valentina Casadio
Journal:  Int J Mol Sci       Date:  2014-07-14       Impact factor: 5.923

10.  Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.

Authors:  Yang Yang; Wen Gao; Xi Ding; Wen Xu; Di Liu; Bo Su; Yifeng Sun
Journal:  Oncotarget       Date:  2017-03-07
View more
  1 in total

1.  A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.

Authors:  Yang Zhang; Erich M Sturgis; Peng Wei; Hongliang Liu; Ziqiao Wang; Yiding Ma; Chuan Liu; Kyle J Gu; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2019-09-12       Impact factor: 4.784

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.